Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT308-Fc3
- Development stage
- Preclinical
- Lead developer
- Emory University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
ANT308-Fc3 is a long-acting recombinant fusion protein consisting of the vasoactive intestinal peptide (VIP) receptor antagonist ANT308 fused to an IgG4 Fc domain. It targets the VIP/VPAC signaling pathway, which functions as a phagocytosis checkpoint in the tumor microenvironment of acute myeloid leukemia (AML), particularly in cases with TP53 mutations. By antagonizing the VPAC1 and VPAC2 receptors, ANT308-Fc3 disrupts the immunosuppressive signaling that prevents macrophages from clearing leukemia cells. Preclinical studies have demonstrated that ANT308-Fc3 can restore macrophage phagocytosis and produce durable leukemia control, supporting its potential as a targeted immunotherapy for high-risk AML.
- Other names
- ANT308-FcANT-308-FcANT 308-FcANT308-IgG4-FcANT-308-IgG4-FcANT 308-IgG4-FcANT308-Fc fusionANT-308-Fc fusionANT 308-Fc fusion
02
Targets
VIPR2 (Vasoactive intestinal polypeptide receptor 2)VIPR1 (Vasoactive intestinal peptide receptor 1)
Beyond the preview
Go deeper on ANT308-Fc3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT308-Fc3.